Skip to main content
. Author manuscript; available in PMC: 2023 Nov 7.
Published in final edited form as: Int J Pharm. 2018 Dec 28;557:178–181. doi: 10.1016/j.ijpharm.2018.12.060

Fig. 3.

Fig. 3.

Cell proliferation assessment following treatment with EPS8 shRNA. NTC: non-targeting control sequence. *p < 0.001 versus no treatment, G4/NTC and G4-EGF/NTC; #p < 0.05 versus G4/EPS8 shRNA.